4basebio and TriLink Advance Phase I Cell Therapy Program
CAMBRIDGE, UK — September 28, 2026 4basebio PLC announced a collaboration with TriLink BioTechnologies, part of Maravai LifeSciences, to...
Genetic Medicines
Advertisement
Precigen Gains FDA Platform Designation for AdenoVerse
Germantown, Maryland, U.S., September 21, 2026 Precigen has announced that the U.S. Food and Drug Administration (FDA) has granted...
Acurx Pharmaceuticals Presents Ibezapolstat C. difficile Data
New York, New York, September 15, 2026 Acurx Pharmaceuticals has announced the presentation of new preclinical microbiology data for...
QurCan Therapeutics and Lilly Advance Nucleic Acid Therapies
Cambridge, Massachusetts, September 15, 2026 QurCan Therapeutics has entered into a strategic research and collaboration agreement with Eli Lilly...
AstraZeneca’s Tozorakimab Cuts COPD Exacerbations in Phase 3
Cambridge, UK, September 8, 2026 AstraZeneca has reported detailed results from the Phase III OBERON and TITANIA trials showing...
Advertisements
NanoMosaic Advances Distributed Genetic Medicine Manufacturing
Waltham, Massachusetts, USA, September 8, 2026 NanoMosaic has joined a Mass General Brigham-led consortium selected for the Advanced Research...
Tangram Therapeutics Advances TGM-312 Into MASH Patient Cohorts
London, UK, September 3, 2026 Tangram Therapeutics announced that its investigational MASH treatment TGM-312 has progressed into Part B...
4basebio and Genezen Expand Synthetic DNA Collaboration
CAMBRIDGE, UK and INDIANAPOLIS, IN — August 26, 2026 4basebio PLC and Genezen announced an expanded, non-exclusive strategic collaboration...
Lilly Acquires Engage Bio for Genetic Medicines
SAN CARLOS, Calif., May 22, 2026 Eli Lilly and Company has acquired Engage Bio, a preclinical biotechnology company focused...
Alloy and Biogen Partner on Antisense Drug Platform
BOSTON, Massachusetts, United States, April 7, 2026 Alloy Therapeutics Inc. announced a multi-target collaboration and license agreement with Biogen...
Advertisement
